Minimal Residual Disease Market Size Worth USD 7.20 Billion by 2034 | CAGR: 13.1%

The global minimal residual disease market size is expected to reach USD 7.20 billion by 2034, according to a new study by Polaris Market Research. The report “Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End User; By Region; Segment Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased prevalence of hematological malignancy and cancer, as well as rising healthcare spending, are expected to drive growth in the minimal residual disease sector throughout the forecast period. Additionally, rising consumer awareness of customized therapy and expanding investments in MRD research by public and private entities are both assisting in the market's expansion. Growth in the market is being slowed down by the heavy price of R&D activities.

The appropriate clinical evidence is used to successfully manage cancer therapies to prevent a residue of tumorous cells, and they are also tailored based on unique progression profiles in each individual. The necessity to consider a patient's unique genetic traits in order to provide effective therapy is being driven by several research studies.

The rising number of cancer patients and the rise in R&D spending are the two main factors driving the market. In addition, the industry is expanding due to the growing use of next-generation sequencing (NGS) technologies. Additionally, the technological developments in diagnostics and therapies brought about by rising R&D expenditures are what's fueling the market's expansion.

Minimal Residual Disease Market Report Highlights

• North America led the global market in 2025, capturing a 45.7% revenue share, driven by high awareness among patients and healthcare professionals and the extensive use of advanced screening technologies.
• Asia Pacific is anticipated to experience robust growth at a 15.2% CAGR during the forecast period, fueled by the increasing burden of cancer and greater accessibility to advanced diagnostic solutions.
• Europe is projected to expand at a 12.4% CAGR during the projected period. It is supported by its well-established healthcare infrastructure and growing investments in precision medicine and advanced cancer diagnostics.
• The leukemia segment held the largest market share of 38.6% in 2025. The growth is fueled by the significant prevalence of blood cancers and the growing emphasis on early diagnosis and continuous disease monitoring.
• Flow cytometry emerged as the leading technology segment, accounting for a 34.8% share in 2025. This is supported by its strong sensitivity, accuracy, and wide applicability in minimal residual disease (MRD) testing.
• Global players with a global presence include Invivoscribe, NeoGenomics Laboratories, Bio-Rad Laboratories, Opko Health, Adaptive Biotechnologies, Natera, Inivata, Sysmex Corporation, Quest Diagnostics, and others.

Request a free sample copy or read the full market insights: Minimal Residual Disease Market Report

Polaris Market Research has segmented the Minimal Residual Disease Market report based on detection target, test technique, end user, and region:

Minimal Residual Disease, Detection Target Outlook (Revenue - USD Billion, 2021 - 2034)

• Lymphoma
• Leukemia
• Solid Tumors
• Multiple Myeloma
• Others

Minimal Residual Disease, Test Technique Outlook (Revenue - USD Billion, 2021 - 2034)

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

Minimal Residual Disease, End User Outlook (Revenue - USD Billion, 2021 - 2034)

• Hospitals and Specialty Clinics
• Laboratory Centers

Minimal Residual Disease, Regional Outlook (Revenue - USD Billion, 2021 - 2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
• Latin America
  • Argentina
  • Brazil
  • Mexico
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa